EP2424507A4 - Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète - Google Patents

Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète

Info

Publication number
EP2424507A4
EP2424507A4 EP10770213A EP10770213A EP2424507A4 EP 2424507 A4 EP2424507 A4 EP 2424507A4 EP 10770213 A EP10770213 A EP 10770213A EP 10770213 A EP10770213 A EP 10770213A EP 2424507 A4 EP2424507 A4 EP 2424507A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
diabetes mellitus
insulin resistance
treating insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10770213A
Other languages
German (de)
English (en)
Other versions
EP2424507A1 (fr
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2424507A1 publication Critical patent/EP2424507A1/fr
Publication of EP2424507A4 publication Critical patent/EP2424507A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP10770213A 2009-04-27 2010-04-27 Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète Withdrawn EP2424507A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (fr) 2009-04-27 2010-04-27 Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète

Publications (2)

Publication Number Publication Date
EP2424507A1 EP2424507A1 (fr) 2012-03-07
EP2424507A4 true EP2424507A4 (fr) 2012-10-24

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10770213A Withdrawn EP2424507A4 (fr) 2009-04-27 2010-04-27 Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète

Country Status (9)

Country Link
EP (1) EP2424507A4 (fr)
JP (2) JP2012525396A (fr)
CN (1) CN102413817B (fr)
AU (1) AU2010241736B2 (fr)
BR (1) BRPI1013992A2 (fr)
CA (1) CA2758738A1 (fr)
IL (1) IL215925A0 (fr)
MX (1) MX2011011333A (fr)
WO (1) WO2010126908A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
ES2747755T3 (es) 2009-01-29 2020-03-11 Forsight Vision4 Inc Administración de un fármaco al segmento posterior
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
PL2600812T3 (pl) 2010-08-05 2022-01-24 Forsight Vision4, Inc. Urządzenie do leczenia oczu
PT2600930T (pt) 2010-08-05 2021-03-22 Forsight Vision4 Inc Aparelho injetor e método para distribuição de fármacos
WO2012019139A1 (fr) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Procédés et appareils d'administration combinée de médicament
WO2012021856A1 (fr) 2010-08-12 2012-02-16 Revalesio Corporation Compositions et méthodes pour traiter une tauopathie
KR102117282B1 (ko) * 2010-11-15 2020-06-01 베링거 인겔하임 인터내셔날 게엠베하 혈관보호성 및 심장보호성 항당뇨 치료요법
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2818612C (fr) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Formulations d'agents therapeutiques pour des dispositifs implantes
JP2014511879A (ja) * 2011-04-13 2014-05-19 レバレジオ コーポレイション 炎症性神経変性疾患に関与するエフェクターｔ細胞を抑制および／または調節する組成物および方法
WO2013003620A2 (fr) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Procédés et appareil de diagnostic
EP3903733A1 (fr) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Appareil d'échange de fluide
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CH706747A2 (de) * 2012-07-17 2014-01-31 Hanspeter Steffen Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
WO2014152959A1 (fr) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
WO2015099201A1 (fr) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Composition contenant des nanobulles, et son utilisation
MY182497A (en) 2014-07-15 2021-01-25 Forsight Vision4 Inc Ocular implant delivery device and method
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
JP6674748B2 (ja) * 2015-05-27 2020-04-01 花王株式会社 Ｇｌｐ−１分泌促進剤
JP6912475B2 (ja) 2015-11-20 2021-08-04 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 持続放出性薬物送達機器用の多孔質構造体
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
CN105878194A (zh) * 2016-06-07 2016-08-24 沈阳药科大学 一种格列本脲纳米结晶制剂及其制备方法
CN106362166B (zh) * 2016-10-27 2019-12-10 武汉大学 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3082891A1 (fr) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Appareil d'echange de fluide pour systeme d'administration a port extensible et methodes d'utilisation
CN110006871A (zh) * 2019-02-20 2019-07-12 常州大学 一个基于外源性组胺检测的细胞模型以及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (fr) * 1990-10-02 1992-04-16 Buchholz Klaus L Utilisation du produit de reaction entre un gaz et un liquide, procede et dispositif de production de celui-ci
WO2002060458A2 (fr) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions et procede de superoxygenation tissulaire
WO2006133113A2 (fr) * 2005-06-03 2006-12-14 BAGLEY David Systeme pour la fabrication et le conditionnement d'eau suroxygenee et structuree
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
WO2009055729A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour traiter une inflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US8591957B2 (en) * 2006-10-25 2013-11-26 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (ja) * 2006-12-26 2008-07-10 Hydrox Kk 抗酸化性機能水

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (fr) * 1990-10-02 1992-04-16 Buchholz Klaus L Utilisation du produit de reaction entre un gaz et un liquide, procede et dispositif de production de celui-ci
WO2002060458A2 (fr) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions et procede de superoxygenation tissulaire
WO2006133113A2 (fr) * 2005-06-03 2006-12-14 BAGLEY David Systeme pour la fabrication et le conditionnement d'eau suroxygenee et structuree
WO2008052143A2 (fr) * 2006-10-25 2008-05-02 Revalesio Corporation Dispositif de mélange et ses fluides de sortie
WO2009055614A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour moduler la transduction de signal intracellulaire véhiculé par membrane cellulaire
WO2009055729A1 (fr) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour traiter une inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010126908A1 *

Also Published As

Publication number Publication date
AU2010241736A1 (en) 2011-12-22
CN102413817A (zh) 2012-04-11
IL215925A0 (en) 2011-12-29
JP2012525396A (ja) 2012-10-22
MX2011011333A (es) 2011-11-18
BRPI1013992A2 (pt) 2016-08-16
EP2424507A1 (fr) 2012-03-07
WO2010126908A1 (fr) 2010-11-04
JP2015229678A (ja) 2015-12-21
CN102413817B (zh) 2014-12-17
AU2010241736B2 (en) 2016-01-28
CA2758738A1 (fr) 2010-11-04

Similar Documents

Publication Publication Date Title
EP2424507A4 (fr) Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète
HK1224144A1 (zh) 用於體重管理和改善血糖控制的方法和組合物
IL205554A (en) An insulin resistance treatment containing melanocortin
ZA201200224B (en) Long acting insulin composition
EP2252312A4 (fr) Procédé de prévention ou de traitement de la résistance à l'insuline
EP2120959A4 (fr) Procédés et compositions destinés au traitement de la résistance à l'insuline, du diabète et d'une dyslipidémie associée au diabète
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
HK1161275A1 (en) Halogen-stabilized insulin
EP2414535A4 (fr) Biomarqueurs liés à la résistance à l'insuline et leurs procédés d'utilisation
ZA201100056B (en) Syringe with disabling mechanism
HK1164112A1 (en) Treating hyperglycemia with glp-1 glp-1
IL207371A0 (en) Injection syringe
SI2376077T1 (sl) Sestavek in metoda za zdravljenje diabetesa
EP2067781A4 (fr) Agent pour améliorer la résistance à l'insuline
EP2386624A4 (fr) Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation
EP2480246A4 (fr) Composition et procédé pour le traitement du diabète
HK1145452A1 (en) A pharmaceutical composition for treating diabetic nephropathy and the preparation method thereof
GB201009713D0 (en) A pharmaceutical composition for treating diabetes and preparation methods thereof
EP2797619A4 (fr) Compositions à base de glypican-4 et procédés destinés au traitement et au diagnostic d'une résistance à l'insuline
PL2557920T3 (pl) Kompozycja zawierająca sproszkowaną błonę skorupy jajka przeznaczona do wykorzystania w terapii cukrzycy
PT2459207E (pt) Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
HK1157690A1 (en) Syringe
EP2035031A4 (fr) Composition d'insuline
GB0812019D0 (en) Insulin
EP2455090A4 (fr) Agent pour l inhibition de l augmentation du taux d insuline postprandiale dans le sang

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20120920BHEP

Ipc: A61K 9/08 20060101ALI20120920BHEP

Ipc: A61K 31/58 20060101ALI20120920BHEP

Ipc: A61K 33/00 20060101ALI20120920BHEP

Ipc: A61K 9/00 20060101ALI20120920BHEP

Ipc: A61K 45/06 20060101ALI20120920BHEP

Ipc: A61K 9/14 20060101AFI20120920BHEP

17Q First examination report despatched

Effective date: 20151008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171103